| Drug ID: | Drug61 |
|---|---|
| Drug Name: | Creatine monohydrate |
| CID: | 80116 |
| DrugBank ID: | NULL |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT02463305 |
| Molecular Formula: | C4H11N3O3 |
| Molecular Weight: | 149.15 g/mol |
| Isomeric SMILES: | CN(CC(=O)O)C(=N)N.O |
| Synonyms: | Creatine monohydrate; 6020-87-7; Creatine, monohydrate; Creapure; Glycine, N-(aminoiminomethyl)-N-methyl-, monohydrate; UNII-9603LN7R2Q; 9603LN7R2Q; N-(Aminoiminomethyl)-N-methylglycine monohydrate; DTXSID10208954; CREATINE MONOHYDRATE [WHO-DD] |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT02463305 | Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD) | EARLY_PHASE1 | WITHDRAWN | University of Colorado, Denver | Colitis, Ulcerative | DRUG: Creatine monohydrate|OTHER: Placebo | Details |
| NCT05687474 | Universal Genomic Newborn Screening in the Wallonia-Brussels Federation: Baby Detect | Not Available | Recruiting | Centre Hospitalier Universitaire de Liege | Congenital Adrenal Hyperplasia;Familial Hyperinsu… | None | Details |
| NCT01793168 | Coordination of Rare Diseases at Sanford | Not Available | Recruiting | Sanford Health | Rare Disorders;Undiagnosed Disorders;Disorders of… | None | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Pyoderma gangrenosum in a patient on ixekizumab
PMID: 34621941
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Based on theoretical considerations, experimental data with cells in vitro, animal studies in vivo, as well as a single case pilot study with one co…